Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Latest Results: Q1 2015 Quarterly
2nd Quarter 2015 Conference Call
Aug 11 2015
Conference ID: 13614378
- Aug 4 2015 8:00 AM EDT Cancer Genetics to Report Second Quarter Financial Results on Tuesday, August 11
- Aug 3 2015 8:00 AM EDT Cancer Genetics to Present a Unique, Comprehensive NGS-Based Lymphoma Panel at Cancer Genomics Consortium and Cytogenomics Array Group Meeting
- Jul 24 2015 8:00 AM EDT Cancer Genetics, Inc. Announced Today That it Has Suspended Its Activity on the "At-The-Market" Equity Offering
Cancer Genetics, Inc.
201 Route 17 North
Rutherford, NJ 07070
Life Science Advisors LLC